2024 ASCO GU | 全球盛会亮点“剧透”抢先看!医脉通邀您一览ASCO GU中国专家相关研究
发布时间:2023-12-18   |   来源:医脉通
关键词: 2024 ASCO GU 中国专家


2024年美国临床肿瘤学会泌尿男生殖系肿瘤分会(ASCO-GU)年会将于当地时间2024年1月25日至27日在旧金山盛大召开。ASCO GU是泌尿男生殖系肿瘤领域的学术盛会,会议将展示该领域最具创新性的科学进展,并探讨泌尿男生殖系肿瘤未来的治疗方向。我国专家有多项研究将于本届盛会亮相世界学术舞台,医脉通邀您先睹为快!


Poster Session

壁报专场


前列腺癌


01 摘要号:133

标题:The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).

讲者:郭宏骞

单位:南京鼓楼医院

海报号:F4


02 摘要号:146
标题:Efficacy and safety between first-line therapies in metastatic castration-resistant prostate cancer in combination in the PARPi and ARSI era: A systematic review and network meta-analysis.

讲者:Xuanjun Guo

单位:北京大学第一医院

海报号:F17


03 摘要号:167
标题:The prognostic value of ductal adenocarcinoma of the prostate in patients with advanced prostate cancer treated with abiraterone acetate.

讲者:Yifu Shi

单位:四川大学华西医院

海报号:G17


04 摘要号:176
标题:Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki-67.

讲者:Fengnian Zhao

单位:四川大学华西医院

海报号:H5


05 摘要号:275
标题:Diagnosis of prostate cancer and benign prostatic hyperplasia based on urinary cell-free DNA methylation characteristics.

讲者:Haoran Tang

单位:慧渡(上海)医疗科技有限公司

海报号:L10


06 摘要号:321
标题:Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.

讲者:庄君龙

单位:南京鼓楼医院

海报号:N12


07 摘要号:327
标题:Neoadjuvant pamiparib plus abiraterone and ADT for high-risk/very high-risk localized prostate cancer: Results of a prospective study.

讲者:庄君龙

单位:南京鼓楼医院

海报号:N18


尿路上皮癌


08 摘要号:591
标题:A phase II study of tislelizumab (T) monotherapy as neoadjuvant treatment for cisplatin-ineligible high risk upper tract urothelial carcinoma (UTUC).

讲者:黄吉炜

单位:上海交通大学医学院附属仁济医院

海报号:F18


09 摘要号:593
标题:Blue light cystoscopy versus white light cystoscopy for the detection of bladder cancer in China: An analysis of unpublished clinical trial and real-world data.

讲者:李汉忠

单位:北京协和医院

海报号:F20


10 摘要号:596
标题:Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.

讲者:曾宇

单位:辽宁省肿瘤医院

海报号:G2


11 摘要号:615
标题:Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.

讲者:沈益君

单位:复旦大学附属肿瘤医院

海报号:G21


12 摘要号:618

标题:Punch: Preliminary results from a phase II study of intra‑arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).

讲者:王宗任

单位:中山大学附属第一医院

海报号:H3


13 摘要号:619

标题:Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node‐positive bladder cancer: Results of a prospective study.

讲者:Xiao Yang

单位:南京医科大学第一附属医院

海报号:H4


14 摘要号:622

标题:Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).

讲者:叶定伟

单位:复旦大学附属肿瘤医院

海报号:H7


15 摘要号:623

标题:Performance of the OncoUrine test on predicting patients who can avoid Re-TURBT and prognosis: A prospective, multicenter clinical study.

讲者:Xiao Yang

单位:南京医科大学第一附属医院

海报号:H8


16 摘要号:631

标题:Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer.

讲者:李成龙

单位:武汉大学人民医院

海报号:H16


17 摘要号:636

标题:Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.

讲者:毕新刚

单位:中国医学科学院肿瘤医院

海报号:H21


18 摘要号:644

标题:RC48-ADC versus BCG in adjuvant treatment of high-risk non-muscle-invasive bladder cancer with HER2 over-expression: A real-world retrospective study.

讲者:Haoyang Liu

单位:四川大学华西医院

海报号:J8


19 摘要号:655

标题:Mutational signature and prognosis in adenocarcinoma of bladder.

讲者:杨国良

单位:上海交通大学医学院附属仁济医院

海报号:J19


20 摘要号:659

标题:Predictive roles of NETs and IgG in neoadjuvant chemotherapy for muscle-invasive bladder cancer.

讲者:Bing-Qing Shang

单位:中国医学科学院肿瘤医院

海报号:K3


21 摘要号:699

标题:The impact and mechanisms of gut microbiota on the efficacy of neoadjuvant therapy in patients with MIBC.

讲者:Tao Li

单位:西安交通大学第一附属医院

海报号:K14


22 摘要号:671

标题:Applying fragmentomics profiles of urinary cell-free DNA for bladder cancer detection.

讲者:Ruiyun Zhang

单位:上海交通大学医学院附属仁济医院

海报号:K15


肾细胞癌;肾上腺癌、阴茎癌和睾丸癌


23 摘要号:420
标题:A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).

讲者:张顺

单位:南京鼓楼医院

海报号:H2


24 摘要号:427
标题:Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immunotherapy: A systematic review and meta-analysis.

讲者:Fengnian Zhao

单位:四川大学华西医院

海报号:H9


25 摘要号:429
标题:Outcomes and prognostic factors of first-line combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in TFE3-rearranged renal cell carcinoma.

讲者:Junjie Zhao

单位:四川大学华西医院

海报号:H11


26 摘要号:431
标题:Immune-related adverse events (irAEs) and the association with clinical outcomes in advanced genitourinary cancers treated with immunotherapy: A systematic review and meta-analysis.

讲者:Yaowen Zhang

单位:四川大学华西医院

海报号:H13


27 摘要号:441

标题:Neutrophil extracellular traps in relation to efficacy of systemic therapy for metastatic renal cell carcinoma.

讲者:Rui-Yang Xie

单位:北京大学第三医院

海报号:J2


28 摘要号:442
标题:Serum IgG: A potential biomarker for predicting the efficacy of systemic therapy in metastatic renal cell carcinoma.

讲者:Honglei Cui

单位:中国医学科学院肿瘤医院

海报号:J3


29 摘要号:443
标题:High expression of sialylated cancer-derived IgG and survival in metastatic clear cell renal cell carcinoma.

讲者:Jie Wu

单位:中国医学科学院肿瘤医院

海报号:J4


30 摘要号:462
标题:Clinicopathological features and transcriptomic profiles of MED15-TFE3-rearranged renal cell carcinoma: A retrospective study of 14 cases.

讲者:Sike He

单位:四川大学华西医院

海报号:K3


31 摘要号:466
标题:The immune characteristic analysis of BAP1 mutated clear cell renal cell carcinoma.

讲者:Zilin Wang

单位:四川大学华西医院

海报号:K7


32 摘要号:507
标题:A novel radiomics-miRNAs integrated model to predict the histopathology of residual retroperitoneal masses in metastatic nonseminomatous germ cell tumors.

讲者:李向东

单位:中山大学肿瘤防治中心

海报号:L9


Trials in Progress Poster Session

进行中的试验海报专场


33 摘要号:TPS233
标题:Clinical study of rezvilutamide inhibiting the flare effect of GnRH agonists in the treatment of newly diagnosed metastatic prostate cancer.

讲者:王少刚

单位:华中科技大学同济医学院附属同济医院

海报号:P16


34 摘要号:TPS355
标题:Rezvilutamide in combination with androgen-deprivation therapy, with or without salvage radiotherapy, for patients experiencing biochemical recurrence following radical prostatectomy: A multi-center, open-label, two-cohort study.

讲者:张顺

单位:南京鼓楼医院

海报号:R7


35 摘要号:TPS718
标题:WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma—A phase II multi-center study.

讲者:鲍一歌

单位:四川大学华西医院

海报号:M18


备注:排名不分先后,按照摘要号进行排序

如有遗漏或任何问题,请给我们留言~


(本网站所有内容,凡注明来源为"医脉通",版权均归医脉通所有,未经授权,任何媒体、网站或个人不得转载,否则将追究法律责任,授权转载时须注明"来源:医脉通"。本网注明来源为其他媒体的内容为转载,转载仅作观点分享,版权归原作者所有,如有侵犯版权,请及时联系我们。)
0
收藏
添加表情
全部评论
我要投稿
发表评论
扫码分享

微信扫码分享

回到顶部